VENTANA PD-L1 (SP263) Assay
PD-L1 predictive assay | Guiding immunotherapy
A new option for identifying NSCLC patients most likely to benefit from OPDIVO® (nivolumab).
Non-small cell lung cancer
Empowering pathologists to answer
Using an approved assay to determine PD-L1 status for immunotherapy options is important. The VENTANA PD-L1 (SP263) Assay is optimized for use on VENTANA BenchMark instruments.
PD-L1 analytic assay
VENTANA analytic assays evaluate for expression of PD-L1 in tumor and immune cells in the context of the tumor microenvironment.